Physician profile
Thomas Kim
NPI 1033179072
$5,305.36
in general payments reported to CMS, 2019-2025
37 companies · $1,387 in 2025
The $1,387 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $141 · 2021: $441 · 2022: $859 · 2023: $1,059 · 2024: $944 · 2025: $1,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,389.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,079.42 | 2021-2025 | |
| Abbvie INC. | $692.77 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $465.41 | 2019-2025 | Winlevi, Blu-U, Odomzo |
| Incyte Corporation | $430.30 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $334.57 | 2020-2025 | Adbry, Anzupgo |
| Amgen INC. | $218.72 | 2022-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $208.01 | 2019-2025 | |
| Galderma Laboratories, L.P. | $195.84 | 2019-2025 | Nemluvio, Aklief |
| Pfizer INC. | $188.78 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $187.03 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $170.58 | 2022-2025 | Tremfya |
| Ucb, INC. | $161.22 | 2019-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $152.00 | 2019 | |
| Biofrontera INC. | $112.35 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Lilly USA, LLC | $102.90 | 2019-2025 | Taltz, Ebglyss, Olumiant |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $90.16 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $82.08 | 2022-2025 | Libtayo |
| Medimetriks Pharmaceuticals, INC. | $37.29 | 2023-2025 | Genadur |
| E.R. Squibb & Sons, L.L.C. | $29.34 | 2024 | Sotyktu |
| Blueprint Medicines Corporation | $27.84 | 2023 | |
| Sanofi-Aventis U.S. LLC | $24.55 | 2020 | |
| Medtronic, INC. | $24.31 | 2025 | Venaseal |
| Verrica Pharmaceuticals INC. | $24.25 | 2024 | Ycanth |
| Mimedx Group, INC. | $23.92 | 2025 | |
| Smith+Nephew, INC. | $23.30 | 2024 | Grafix Pl |
| Mission Pharmacal Company | $22.73 | 2019 | |
| Kyowa Kirin, INC. | $22.31 | 2023 | Poteligeo |
| Cipher Pharmaceuticals US LLC | $21.56 | 2025 | Natroba, Spinosad |
| Organogenesis INC. | $21.30 | 2025 | Puraply Wound Matrix |
| Botanix Sb INC | $19.80 | 2025 | Sofdra |
| Celgene Corporation | $19.16 | 2019 | |
| Dusa Pharmaceuticals, INC. | $18.15 | 2019 | |
| Almirall LLC | $16.70 | 2021 | |
| Prugen, INC. Pharmaceuticals | $15.10 | 2019 | |
| Epi Health, LLC | $13.95 | 2019 | |
| Journey Medical Corporation | $13.91 | 2022 | |
| Sebela Pharmaceuticals INC. | $13.75 | 2023 | Naftin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.